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A b s t r a c t
Background: Pacing leads remain the weakest link in pacemaker systems despite advances in manufacturing technology.
Aim: The aim of the study was to assess the long-term pacing lead performance in an unselected real-life cohort following 
primary DDD pacing system implantation.
Methods: A single-centre retrospective analysis of patients who underwent DDD pacing system implantation between October 
1984 and December 2014 and were followed-up until August 2016 was conducted. The inclusion criterion was at least one 
follow-up visit after post-implant discharge. The performance of each atrial and ventricular lead implanted was evaluated 
during the follow-up period, and the incidence of, and predictive factors for, lead dislodgement and failure were analysed.
Results: The data of 3771 patients and 24,431.8 patient-years of follow-up were analysed. The mean follow-up of patients 
was 77.7 ± 61.8 months. During the study period, 7887 transvenous atrial and right ventricular pacing leads were implanted. 
Lead dislodgement occurred in 94 (1.2%) leads (92 [2.4%] patients), perforation in 11 (0.1%) leads (10 [0.3%] patients), and 
lead failure in 329 (4.2%) leads (275 [7.3%] patients). Atrial lead position was a predictive factor for lead dislodgement, while 
age at implantation, polyurethane 80A insulation, subclavian vein access, unipolar lead construction, and lead manufacturer 
were multivariate predictors of lead failure.
Conclusions: Leads with polyurethane 80A insulation, unipolar construction, and those implanted via subclavian vein puncture 
exhibited the worst long-term performance.
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INTRODUCTION
Permanent pacemaker technology has evolved considerably 
over the past five decades. Major advancements have been 
made in the design of pacing leads for improved electrical 
performance and patient safety. However, despite significant 
progress, pacing leads have remained the most vulnerable 
component of transvenous pacing systems. Lead-related com-
plications are the primary reason for reoperation following 
cardiac-implantable electronic device implantations [1, 2]. 
Management of displaced and failed leads may require chal-
lenging lead extraction procedures with surgical backup and 
transoesophageal echocardiography monitoring [3, 4]. Further-
more, lead-related interventions are associated with increased 
patient morbidity and healthcare costs [5]. The short-term per-
formance of pacing leads and predictors for early lead-related 
complications have been evaluated in many reports [1, 5–7]. 
However, unlike implantable cardioverter-defibrillator (ICD) 
leads [8, 9], the long-term reliability and chronic performance 
of DDD pacing leads have received less attention. Thus, the 
objectives of the present analysis were to examine whether the 
progress in lead construction technology has affected the rate of 
lead-related complications in an unselected real-life cohort im-
planted with a DDD pacemaker, and to identify the predictors 
of lead dislodgement and lead failure in a long-term follow-up.
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METHODS
The study cohort comprised all consecutive patients who 
underwent primary DDD pacemaker implantation at 
a high-volume tertiary reference university implantation 
centre between 4 October 1984 (the first performed DDD 
pacemaker implantation at the Department of Electrocar-
diology, John Paul II Hospital, Kraków, Poland) and 31 De-
cember 2014. The study inclusion criterion was at least one 
follow-up visit after hospital discharge. Patients who were 
permanently lost to follow-up after hospital discharge were 
excluded from the study. The follow-up was completed on 
31 August 2016. The data used in the analysis included the 
following: (1) patients’ demographic baseline characteristics 
(date of birth, age at primary DDD implantation, age at ad-
ditional lead implantation procedure, and sex); (2) the type 
of venous access (subclavian vein puncture or cephalic vein 
cut-down); (3) the name of the endocardial pacemaker lead 
model; (4) the lead manufacturer; (5) the position of the 
lead (atrial or ventricular); (6) the type of fixation (passive 
or active); (7) lead polarity (unipolar or bipolar); (8) the type 
of lead dysfunction (lead dislodgement, cardiac perforation, 
or lead failure); (9) the date of the diagnosis of lead-related 
complications; (10) the length of lead follow-up, and (11) 
the length of patient follow-up (i.e. time from primary DDD 
pacemaker implantation to the last follow-up visit).
Retrospective data generated on the basis of this analysis 
were retrieved from paper and electronic medical records 
issued during all hospitalisations in our department, other 
departments within our hospital, and from outpatient clinic 
medical files comprising pacemaker follow-up visits as well as 
the documentation of device-related procedures performed 
in other cardiology centres. Lead dislodgement was defined 
as a need for operative adjustment, replacement, or surgical 
abandonment of the lead because of macroscopic dislodge-
ment. Cardiac perforation was defined as radiographic 
evidence of the excursion of the pacing lead into the peri-
cardial sac, with abnormal echocardiography and/or cardiac 
computed tomography findings indicative of a perforation. 
Lead failure due to lead damage was defined as an inappropri-
ately elevated pacing threshold or detection of problems that 
persisted despite device reprogramming and/or out-of-limit 
alterations in lead impedance (< 200 Ω or > 2000 Ω). 
Lead failure was considered only when lead dislodgement 
and cardiac perforation were ruled out during diagnostic 
work-up. Reoperation was not a prerequisite for diagnosing 
lead failure. During most of the study period, implantations 
were performed by a small number of highly experienced car-
diologists. Unipolar leads were implanted between 1984 and 
2002, and bipolar leads were implanted since 1988. Cephalic 
cut-down technique was used for venous access whenever 
possible. The subclavian vein was directly punctured when 
the preparation of the cephalic vein failed or the insertion 
of the second lead was impossible despite the applica-
tion of a modified cephalic vein guidewire technique [10]. 
Axillary vein puncture has not been used in our centre. 
All transvenous atrial and ventricular pacing leads implanted 
were examined during the follow-up period. The perfor-
mance of right ventricular cardioverter-defibrillator leads, 
right ventricular VDD leads, transvenous left ventricular leads, 
and epicardial leads implanted in our patient cohort was not 
assessed in the present study. The duration of lead follow-up 
was defined as the period between lead implantation and 
whichever of the following that occurred first: total lead frac-
ture visible on chest X-rays with ineffectual capture/no sensing 
and abnormal impedance at device interrogation, surgical 
lead abandonment, lead extraction, or the last follow-up visit.
Statistical analysis
The data were evaluated using IBM SPSS Statistics for 
Windows, version 25 (IBM Corp., Armonk, NY, USA). 
Normality was tested using Shapiro-Wilk test (S-W) for 
samples ≤ 2000 and Kolmogorov-Smirnov test (K-S) for 
samples > 2000. Continuous variables are expressed as 
mean ± standard deviation and additionally as median and 
interquartile range (IQR) for variables with non-normal dis-
tribution. Categorical variables were compared using c2 test. 
Cumulative survival rates were calculated according to the 
Kaplan-Meier method. Event times were measured from the 
time of each lead implantation procedure. The significance 
of differences between the considered variables in terms of 
lead survival was assessed using the log-rank test. The prog-
nostic impact of selected variables on lead dislodgement 
was assessed using univariate logistic regression model. The 
association between selected variables and lead failure was 
assessed using the Cox proportional hazards model. A p-value 
of < 0.05 was considered significant.
RESULTS
During the study period, 3932 consecutive patients underwent 
primary DDD pacemaker implantation. After hospital dis-
charge, 161 patients were lost to follow-up and were thereby 
excluded from the analysis. The data of 3771 patients and 
24,431.8 patient-years of follow-up were analysed. The mean 
duration of follow-up was 77.7 ± 61.8, median 62.5, IQR 
78.2 months (max. 369.5 months) (K-S; p < 0.001). During 
the study period, 7887 transvenous atrial and right ventricular 
pacing leads were implanted: 7542 during initial DDD pace-
maker implantation and 345 during device revisions after either 
lead explantation or lead abandonment; 3060 (38.8%) leads 
had passive fixation and 4827 (61.2%) leads had active fixa-
tion; 349 (4.4%) leads were unipolar and 7538 (95.6%) leads 
were bipolar. Atrial lead fixation was passive in 1533 (38.7%) 
leads and active in 2428 (61.7%) leads, whereas ventricular 
lead fixation was passive in 1527 (38.9%) leads and active in 
2399 (61.8%) leads. The lead model names, manufacturers, 
types of insulation and the exact number of leads and lead 
failures are summarised in Table 1. The mean patient age 
at lead implantation was 69.8 ± 12.1 (15.2–96.6), median 
www.kardiologiapolska.pl
Lead-related complications after DDD pacemaker implantation
1225
Table 1. Lead manufacturers, lead model names with their insulation, polarity and position, number, and rate of lead failure.  
If not specified, the lead insulation was silicone
Manufacturer Lead  
model
Insulation Unipolar Bipolar Atrial Ventricular Lead  
failure
Failure rate  
[%]
Biotronik DJP + 34 9 26.5
DN/DNR + 20 7 35
Elox + 7 1 14.3
+ 15 3 20
JP + 24 1 4.2
PE 60/4-DN + 13 8 61.5
PE 603-DJ + 14 9 64.3
Polyrox J + 50 3 6
Polyrox + 29 0 0
Retrox J + 4 0 0
SD + 12 2 16.7
Selox SR + 25 0 0
+ 22 1 4.5
Selox ST + 91 3 3.3
Selox JT + 98 1 1
Setrox S + 152 2 1.3
+ 138 2 1.4
Siello + 327 0 0
+ 296 1 0.3
Solia + 17 0 0
+ 17 0 0
SR-60-UP + 1 0 0
+ 1 0 0
Synox + 688 19 2.8
+ 644 14 2.2
TIJ + 102 21 20.6
+ 379 31 8.2
TIR + 123 10 8.1
+ 412 20 4.9
Y + 9 1 11.1
+ 4 0 0
YP + 1 0 0
+ 1 0 0
+ 1 0 0
+ 10 0 0
Biotronik failure rate [%] 20.6 3 5.1 3.8 4.5
Medtronic 4082 PU 80A + 1 0 0
6957 PU 80A + 2 1 50
4004/4004M PU 80A + 14 8 57.1
4504M PU 80A + 15 2 13.3
4068 PU 80A + 1 0 0
4557 PU 80A + 5 0 0
5024M + 6 0 0
5524M + 7 1 14.3
5054 + 8 0 0
5554 + 12 1 8.3
Æ
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71.9, IQR 14.2 years (K-S; p < 0.001). Considering each lead 
placement separately, 4210 (53.4%) leads were implanted in 
male patients and 3677 (46.6%) in female patients. The mean 
duration of lead follow-up was 73.2 ± 59.5, median 58.3, IQR 
73.1 months (max. 369.5 months) (K-S; p < 0.001).
Subclavian vein access was used for 4950 (62.8%) leads 
and cephalic vein access for 2937 (37.2%) leads. Ventricular 
leads were more frequently inserted via the cephalic vein 
(2379 [60.6%]) than via the subclavian vein (1546 [39.4%]), 
whereas atrial leads were more frequently inserted via the 
subclavian vein (3404 [85.9%]) than via the cephalic vein 
(558 [14.1%]). The choice of venous access was not associated 
with patient’s sex (c2 = 1.35; p = 0.245).
Lead dysfunction occurred in 434 (5.5%) leads: 11 (0.1%) 
were confirmed to have perforated the heart, 94 (1.2%) dis-
lodged, and 329 (4.2%) failed. Lead dislodgement occurred 
in 92 (2.4%) patients, perforation in 10 (0.3%) patients, and 
lead failure in 275 (7.3%) patients. Regarding manufacturers, 
50 (1.3%) of the dislodged leads were manufactured by Bio-
tronik (Berlin, Germany), 34 (1%) by Medtronic (Minneapolis, 
MN, USA), and 10 (1.3%) by Vitatron (Maastricht, Netherlands); 
furthermore, 169 (4.5%) of the failed leads were manufactured 
by Biotronik, 98 (3%) by Medtronic, 50 (6.4%) by Vitatron, and 
12 (22.2%) by other manufacturers.
Predictors of lead dislodgement and lead failure are 
shown in Figures 1 and 2, respectively.
Predictors of lead dislodgement
In the univariate logistic regression analysis performed at lead 
implantation, atrial lead position was the only independent 
predictor of lead dislodgement. The association between 
lead dislocation and patient’s sex, age at lead implantation 
(one-year increase), and the type of lead fixation showed no 
deviation from linearity.
Predictors of lead failure
Independent predictors of lead failure measured at lead 
implantation in the multivariable Cox regression model were 
subclavian vein puncture, unipolar lead construction, age at 
the time of implantation, and lead manufacturer. The age at 
the time of implantation inversely influenced lead failure, with 
younger patients having a significantly higher likelihood of lead 
failure (odds ratio 0.985; p < 0.001). With Medtronic leads 
considered as a reference, Vitatron leads were significantly 
associated with an increased risk of lead failure, whereas 
Biotronik leads significantly protected against lead failure. 
Neither lead position (atrial or ventricular) nor patient’s sex 
influenced lead failure.
Actuarial failure-free lead survival rates of unipolar 
leads five, 10, 15, and 20 years after lead implantation were 
90%, 81%, 74%, and 70%, respectively, and those of bipolar 
leads were 98%, 94%, 90%, and 86%, respectively (log-rank 
c2 = 57.253; p < 0.001; Fig. 3). To avoid bias related to the 
Table 1. (cont.) Lead manufacturers, lead model names with their insulation, polarity and position, number, and rate of lead 
failure. If not specified, the lead insulation was silicone
Manufacturer Lead  
model
Insulation Unipolar Bipolar Atrial Ventricular Lead  
failure
Failure rate  
[%]
Medtronic 5068 + 1 0 0
5568 + 51 0 0
4076 PU 55D + 6 0 0
PU 55D + 8 0 0
5076 + 1519 51 3.4
+ 1398 26 1.9
5092 + 129 4 3.1
5592 + 93 4 4.3
Medtronic failure rate [%] 14.3 3 3.5 2.4 3
Vitatron ICF09B + 292 31 10.6
+ 484 19 3.9
Vitatron failure rate [%] 6.4 10.6 3.9 6.4
Other + 11 5 45.5
+ 21 6 28.6
+ 15 1 0.7
+ 7 0 0
Total 349 7538 3961 3926 329 4.2 
PU — polyurethane
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comparison of old unipolar leads with some modern bipolar 
leads, a subanalysis of leads implanted only between 1988 and 
2002 (i.e. between the year of first bipolar lead implantation 
and the year of last unipolar lead implantation) at our centre 
was performed. The analysis confirmed that the performance 
of 337 unipolar leads remained significantly inferior to that 
of 1596 bipolar leads (log-rank c2 = 61.987; p < 0.001). In 
the entire cohort, lead failure occurred at a mean duration of 
73.6 ± 53.3, median 61.0, IQR 64.4 months after implanta-
tion (S-W; p < 0.001). Biotronik bipolar leads failed after 
81.6 ± 57, median 81.4, IQR 83.4 months (S-W; p < 0.003) 
whereas Biotronik unipolar leads failed after 90.4 ± 71.6, me-
dian 63.3, IQR 99.1 months (S-W; p < 0.001); Medtronic and 
Vitatron bipolar leads failed after 61.6 ± 40.4, median 52.3, 
IQR 49.3 months (S-W; p < 0.001) and 57.1 ± 29.2 months 
(S-W; p = 0.439), respectively. Leads insulated with poly-
urethane 80A showed an almost fourfold higher incidence 
of failure than those insulated with silicone (26.5 vs. 6.8 per 
1000 lead-years of follow-up). Among leads insulated with 
polyurethane 55D, we did not observe lead failure during 
a mean of 49.1 ± 18.5, median 57.3, IQR 23.7 months of 
follow-up (S-W; p < 0.012). When considering only bipolar 
leads with silicone insulation (Fig. 4), the performance of 
Biotronik leads was significantly superior to that of Medtronic 
Figure 1. Univariate logistic regression analysis of lead dislodgement; CI — confidence interval; HR — hazard ratio
Figure 2. Multivariable Cox regression analysis of lead failure in all Biotronik, Medtronic, and Vitatron leads (7833 leads);  
CI — confidence interval; HR — hazard ratio
www.kardiologiapolska.pl
Maciej Dębski et al.
1228
leads (p < 0.001), and the performance of Medtronic leads 
was significantly better than that of Vitatron ICF09B leads 
(p = 0.002). The incidence of failure in bipolar silicone-in-
sulated leads was 4.1 per 1000 lead-years of follow-up for 
Biotronik leads, 6.5 per 1000 lead-years of follow-up for 
Medtronic leads, and 12.2 per 1000 lead-years of follow-up 
for Vitatron leads. The largest group of modern bipolar 
active-fixation leads in our study was the Medtronic model 
5076 (2917 leads), with a six-year survival rate of 95.6%.
DISCUSSION
One of the main findings of this study is the very long-term 
data regarding the performance of several types of endocardial 
pacing leads. In the present study, the overall performance 
of the bipolar leads was significantly better than that of the 
unipolar leads. Ten-year survival rates of 94% for bipolar leads 
and 81% for unipolar leads were reported. The significant 
difference persisted when the bipolar leads were compared 
with the unipolar leads implanted in the same period. Our 
data concur with a previously published report by Helguera 
et al. [11], who assessed 2611 leads implanted between 
1980 and 1991 and observed a tendency towards a better 
10-year survival among unipolar leads compared with bipolar 
leads. Furthermore, a register-based report on > 33,000 endo-
cardial pacing leads implanted in Denmark between 1982 and 
1999 revealed that the 10-year survival rate of unipolar leads 
was significantly better than that of bipolar leads despite 
the exclusion of several poorly performing bipolar leads 
from the analysis [12]. However, the authors noted that the 
performance of bipolar leads had been improving and that 
some models achieved an overall survival rate of > 95% at six 
years. The largest group of modern bipolar leads in our study 
was the Medtronic model 5076, with a six-year failure-free 
lead survival rate of 95.6%. Interestingly, this value is lower 
than the officially reported lead survival rate of approximately 
98.5%, according to the Manufacturer’s Product Surveillance 
Registry [13]. Of note, the rate demonstrated by Medtronic 
encompasses all the complications, including cardiac perfora-
tions and lead dislodgements, which were excluded from the 
present lead failure analysis [13]. According to the Swedish 
Pacemaker Registry, the 10-year survival rate of pacemaker 
leads was 98% [14]. The median time to failure for all leads 
in our study was 6.1 years. The analysis of the causes of lead 
failure in 617 explanted failed leads indicated a mean time 
to failure of 7.2 ± 5.2 years [15]. Notably, both Hauser et 
al. [15] and Arnsbo et al. [12] qualified a lead as failed only 
when surgical intervention was performed, whereas we did 
not require reoperation as a clinical criterion to diagnose 
lead failure. 
The data regarding the better survival of Biotronik leads 
compared with Medtronic leads and the worst survival of 
Vitatron ICF09B leads should be interpreted with caution and 
verified in further prospective studies. The poor performance 
of the early Medtronic leads 4004/M and 4504 has been as-
sociated with the use of polyurethane P80A as the insulation 
material. Polyurethane leads have been implanted in humans 
since 1977 [16]. Within four years from the first use of polyu-
rethane 80A in pacing leads, the insulation material was found 
to exhibit surface cracks and clinical evidence of insulation 
failure. The high rate of polyurethane 80A insulation failure 
was observed in coaxial bipolar leads but not in unipolar leads 
[17]. Defects have also been confirmed in Medtronic leads 
4082, 6972, and 4012. This has led to the use of another 
Figure 4. Kaplan-Meier failure-free survival estimate of bipolar 
leads with silicone insulation according to manufacturer.  
Number of leads: Biotronik — 3471, Medtronic — 3224,  
Vitatron — 776. Differences between all groups are significant: 
Biotronik vs. Medtronic (log-rank c2 = 21.041; p < 0.001); 
Medtronic vs. Vitatron (log-rank c2 = 9.603; p = 0.002);  
Biotronik vs. Vitatron (log-rank c2 = 55.035; p < 0.001)
Figure 3. Cumulative lead performance by polarity. Differences be-
tween groups are significant: log-rank c2 = 75.267; p < 0.001
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polymer, polyurethane 55D, which is a more reliable material [18]. 
Insulation with polyurethane 80A was an independent pre-
dictor of lead failure. This observation is in agreement with 
other reports on long-term lead performance [12, 15, 19]. 
Another variable independently associated with lead 
failure was subclavian vein puncture. Subclavian crush syn-
drome is a well-described cause of pacemaker lead failure 
resulting from entrapment of a lead or leads between the 
clavicle and the first rib. Infraclavicular lead failure has been 
associated with soft tissue entrapment in the subclavius muscle 
or the costoclavicular ligament, where the lead undergoes 
repeated episodes of bending and tension during pectoral 
muscle movements [20]. However, whether one technique is 
superior to the other remains debatable [11, 21, 22]. On the 
basis of the records of 409 patients implanted with 681 im-
plantable pacemaker leads and 20 (2.9%) lead failures at 
a mean of 73.6 ± 33.1 months of follow-up, Chan et al. [22] 
recommended axillary vein puncture instead of cephalic vein 
cut-down as the venous access of choice for pacemaker lead 
implantation. Conversely, in the analysis of Sprint Fidelis lead 
failures, Birnie et al. [9] demonstrated that both axillary and 
subclavian accesses increased the hazard of failure compared 
with cephalic access. Reportedly, the need for subclavian vein 
puncture independently increased the mean implantation 
and fluoroscopy times [23]. Our data are strongly supportive 
of the use of cephalic vein cut-down as the first choice of 
venous access and advocate against using subclavian vein 
puncture when possible. Importantly, implanting three leads 
via the cephalic vein for a cardiac resynchronisation therapy 
pacemaker or defibrillator has been demonstrated to be a safe 
and effective first approach technique [24]. 
Regarding the fixation mechanism, in a study investi-
gating the predictors of lead fracture in children, Olgun et 
al. [25] detected an association between the active fixation 
mechanism and lead fractures and postulated that the re-
peated screwing-retraction attempts during implantation may 
have a deleterious effect on the inner coil and consequently 
weaken the lead body. In contrast, Hauser et al. [15] reported 
that active and passive-fixation mechanisms were equally 
represented among leads with malfunction. In the present 
study, the lead fixation mechanism did not predict lead fail-
ure or dislodgement. This is in agreement with a benchmark 
study reporting short-term complications arising after DDD 
pacemaker implantation, in which there was no association 
between the fixation type of atrial or ventricular leads and 
the occurrence of atrial and ventricular lead dislodgement 
or any lead-related complication [6, 26]. Additionally, no 
association was noted between female sex and increased 
risk of failures. A strong correlation between female sex and 
increased risk of failure has been demonstrated for various 
ICD leads [8, 9]. Finally, with each one-year increase in patient 
age, the risk of lead failure decreased. This observation is in 
accordance with the results of the FOLLOWPACE study [26] 
and may be attributed to the increased physical activity of 
younger patients [27] as well as to the bias related to longer 
life expectancy and follow-up duration in younger patients.
The main limitation is the retrospective and single-centre 
design of this study, with all the inherent shortcomings. First, 
because the follow-up visits predominantly occurred once 
a year, a certain number of lead-related complications after the 
last pacemaker interrogation might not have been detected. 
To address this limitation, large prospective studies with te-
lemonitoring are warranted. Second, the fact that we analysed 
the performance of 39 lead models used in different years 
over a three-decade study period rendered the lead model 
follow-up heterogeneous, and the number of patients remains 
too small to demonstrate clinically important differences in 
complication rates between various lead types. Finally, con-
stant innovations in this field lead to a dynamism wherein it 
is difficult to apply conclusions regarding technologies that 
are no longer used.
In conclusion, we assessed the long-term performance of 
7887 transvenous atrial and right ventricular leads in a 10-year 
follow-up and determined survival rates of 81% for unipolar 
leads and 94% for bipolar leads. During 24,431.8 patient-years 
of follow-up, lead failure occurred in 275 (7.3%) patients and 
lead dislodgement in 92 (2.4%) patients. Atrial lead position 
predicted lead dislodgement, whereas fixation type, patient 
sex, or age at the time of implantation did not predict dislo-
cation. Lead manufacturer, unipolar construction, subclavian 
vein access, insulation with polyurethane 80A, and young age 
of patients were independently associated with lead failure.
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WHAT IS NEW?
A retrospective analysis was conducted in consecutive patients who were implanted with dual-chamber pacemakers at 
a tertiary reference cardiology centre between 1984 and 2014 and were followed up in an outpatient pacemaker clinic 
until 2016. With the data of 3771 patients and 24,431.8 patient-years of follow-up, this is one of the largest single-centre 
analyses of lead-related complications. Lead dislodgement occurred in 1.2% of leads, and lead failure occurred in 4.2% 
of leads. Atrial lead position was associated with dislodgement, whereas the type of lead fixation, age, and sex did not 
affect the rate of dislodgement. Independent predictors of lead failure included subclavian vein puncture, unipolar lead 
construction, age at the time of implantation, and lead manufacturer. Moreover, this study compared the outcomes of 
Medtronic and Biotronik leads, revealing the significantly better performance of the latter manufacturer.
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